[Treatment outcomes in patients with unfavorable histologic type of endometrial carcinoma].
Five-year overall and recurrence-free survival was evaluated in 84 stage I endometrial cancer patients with such histological patterns as poorly differentiated endometrioid adenocarcinoma, clear-cell carcinoma, serous papillary cancer, poorly differentiated cancer and mixed-type carcinoma. Overall 5-year survival in the whole group was 60.1 +/- 5.9% while recurrence-free survival--52.1 +/- 5.9%, those rates for poorly differentiated endometrioid adenocarcinoma being 50.8 +/- 7.3% and 41.9 +/- 7.4%, respectively. Our data suggest that combination therapy is ineffective in the management of stage I endometrial carcinoma when histotype of tumor is unfavorable (overall 5-year survival - 56.51 +/- 7.8%; recurrence-free survival--49.7 +/- 7.9%).
Litvinova
T M
TM
Kosenko
I A
IA
D000230:Adenocarcinoma / Q000473:pathology / Q000628:therapy; D018262:Adenocarcinoma, Clear Cell / Q000473:pathology / Q000628:therapy; D000328:Adult; D000368:Aged; D002291:Carcinoma, Papillary / Q000473:pathology / Q000628:therapy; D003131:Combined Modality Therapy; D018572:Disease-Free Survival; D016889:Endometrial Neoplasms / Q000473:pathology* / Q000628:therapy*; D005260:Female; D006801:Humans; D008207:Lymphatic Metastasis; D008875:Middle Aged; D009367:Neoplasm Staging; D016019:Survival Analysis; D016896:Treatment Outcome